<DOC>
	<DOCNO>NCT01493999</DOCNO>
	<brief_summary>MAIN AIM : To compare pharmacological potency administer adjust 600 mg clopidogrel load dos 60 mg prasugrel patient high on-clopidogrel platelet reactivity ( HPR ) PCI . SECONDARY OBJECTIVES : To define optimal maintenance dose prasugrel ( 5 mg vs. 10 mg ) clopidogrel ( 75 mg vs. 150 mg ) patient HPR chronic therapy . DESIGN : Prospective , Randomized , Open-label , Single-center trial . PRIMARY ENDPOINT : Platelet reactivity measure Multiplate clopidogrel prasugrel arm day 4 .</brief_summary>
	<brief_title>Prasugrel Versus Clopidogrel TREAT High Platelet Reactivity</brief_title>
	<detailed_description>Study rationale : After coronary stent implantation , aspirin plus thienopyridine therapy proven superior aspirin alone aspirin plus warfarin reduce adverse thrombotic event . Due low rate haematopoietic side effect , daily administration faster onset action , clopidogrel replace ticlopidine thienopyridine choice patient acute coronary syndrome ( ACS ) percutaneous coronary intervention ( PCI ) . However , clopidogrel many know limitation might carry important clinical consequence . First , onset action clopidogrel relatively slow ; even load dose 600 mg require 4-6 hour achieve full antiplatelet effect . Second , antiplatelet potency clopidogrel moderate , platelet reactivity clopidogrel treatment show wide inter-patient variability . As result , substantial proportion ( 25-30 % ) patient receive proper ADP-receptor inhibition fixed-dose clopidogrel regimen high on-clopidogrel platelet reactivity ( HPR ) might persist despite clopidogrel administration . In meta-analysis comprise 20 study 9,100 patient , HPR 3.4-fold risk cardiovascular death , 3-fold risk myocardial infarction ( MI ) , 4-fold risk definite/probable stent thrombosis . According current knowledge , development HPR multifactorial : clinical condition ( diabetes , acute coronary syndrome , renal insufficiency , low ejection fraction ) , laboratory parameter ( platelet count , baseline platelet reactivity ) , patient compliance genetic predisposition might contribute evolution HPR . ( 13 ) Out factor , clinical importance genetic interaction clopidogrel-treated subject recently emphasize multiple study black-boxed warning FDA . ( 14 ) Based , clopidogrel-treated patient get full clinical benefit clopidogrel therapy carry loss-of-function allele ( LOF : *2 *3 ) CYP2C19 gene high risk adverse thrombotic event . All evidence highlight currently recommend , fixed-dose clopidogrel treatment insufficient prevent development HPR thrombotic event significant proportion patient PCI . Up , limited information optimal strategy overcome HPR . Increasing maintenance dose clopidogrel 150 mg might decrease rate HPR ; however , might help less 50 % patient . In one study , administration repeat load dos 600 mg clopidogrel - base result vasodilator stimulate phosphoprotein phosphorylation ( VASP ) assessment - successful overcome HPR 86 % patient . Importantly , first strategy clopidogrel associate improvement clinical outcome among patient non-ST segment elevation MI , reload group significantly low rate major adverse cardiac event compare conventional fix dose clopidogrel . Beyond clopidogrel , new antiplatelet agent might also attractive candidate overcome HPR . Prasugrel novel , third-generation thienopyridine eliminate many drawback clopidogrel . Compared clopidogrel , prasugrel lead rapid great formation active metabolite absorption inactivate non-specific estherases portal circulation . These feature result rapid , uniform potent platelet inhibition load dose maintenance phase prasugrel compare even high-dose clopidogrel . However , direct comparison platelet inhibition strategy administer repeat loading dos clopidogrel prasugrel patient HPR . Moreover , optimal maintenance dos clopidogrel prasugrel maintain proper platelet inhibition chronic phase antiplatelet therapy also unknown . Thereby , aim compare achievable platelet inhibition 60 mg prasugrel adjust load dos 600 mg clopidogrel tailor accord platelet function assessment patient PCI . Moreover , aim compare antiplatelet potency different clopidogrel ( 75 vs. 150 mg ) prasugrel ( 5 mg vs. 10 mg ) maintenance dose chronic phase PCI . Previous work : Our research team University Pécs , Hungary involve platelet function experiment since five year . We describe large inter-individual variability response clopidogrel demonstrate high on-treatment ADP reactivity associate recurrent ischemic event PCI . We perform meta-analysis summarize clinical significance high platelet reactivity describe patient 3-fold risk MI , 4-fold risk stent thrombosis 3,4-fold risk CV death . We also try determine efficacy 150 mg clopidogrel among patient high platelet reactivity , together clinical laboratory predictor good response high maintenance dose . We compare sophisticated method platelet aggregation light transmission aggregometry . Study hypothesis : We hypothesise prasugrel provide rapid potent platelet aggregation inhibition compare repeat load dos clopidogrel patient HPR PCI . We also test efficacy 5 mg 10 mg prasugrel well 75 150 mg clopidogrel sustain platelet inhibition maintenance phase .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Age 1874 year PCI stent implantation due stable angina acute coronary syndrome Platelet function assessment available 624 hour PCI Multiplatederived ADPreactivity &gt; 47 U Age ≥75 year Prior TIA stroke Body weight less 60 kg Contraindication aspirin / thienopyridines Severe liver failure ( Child Pugh C ) Need oral anticoagulation follow one month Planned discontinuation antiplatelet treatment one month Current bleeding disorder , active bleeding event ( Weber positivity ) Haemoglobin level presentation &lt; 90 g/l Refused informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Clopidogrel</keyword>
	<keyword>prasugrel</keyword>
	<keyword>HPR</keyword>
	<keyword>load dose</keyword>
	<keyword>maintenance dose</keyword>
	<keyword>stent thrombosis</keyword>
	<keyword>platelet reactivity</keyword>
	<keyword>Coronary intervention</keyword>
	<keyword>stent implantation</keyword>
</DOC>